The August issue of the Journal of Drugs in Dermatology (JDD) focuses on Psoriasis and features mix of original articles, editorials, and case reports. Among many of the topics explored in this issue are treatment of scalp psoriasis, nail psoriasis, respiratory tract infections in patients using biologics for hidradenitis suppurativa, classification of actinic keratosis, lichen planus pigmentosus in children, and many more. Check out this month’s issue highlights straight from the JDD Editor’s desk:
The Incidence and Risk of Respiratory Tract Infections in Patients Using Biologics for Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis examines 9 studies including 5 placebo-controlled studies of patients with moderate to severe HS treated with biological therapy.
In New Biologics and Oral Drugs in Treatment of Moderate to Severe Psoriasis, authors perform a database search for English-language literature regarding phase 2 and phase 3 trial drugs.
Treatment of Scalp Psoriasis concludes that topical treatment, particularly topical corticosteroids or their combination with vitamin D analogues, remains the first line of management.
Patients desire more effective, faster, longer acting, less costly, and more accessible treatments in Unmet Needs in Psoriasis Patients
Classifying Actinic Keratosis: What the Reality of Everyday Clinical Practice Shows Us suggests avoiding applying classifications such as the Olsen grading system, which do not improve routine clinical practice and appropriate treatment selection.
Systematic Review of Lichen Planus Pigmentosus in Children advises that LPP can follow four patterns: common, inverse, palmoplantar, and linear.
Onset of Plaque Psoriasis Treatment Responses With Anti–IL-17/IL-23 Biologic Therapies determines that Brodalumab is associated with the most rapid times to achieve PASI 90 and PASI 100, compared with other options.
Timeline: The Evolution of Fellowship Training in Micrographic Surgery and Dermatologic Oncology chronicles the history and development of the subspecialty.
Single-Centre Real-Life Experience of Guselkumab in Patients with Moderate-to-Severe Plaque Psoriasis confirms that the drug is an effective and safe biologic agent capable of maintaining long-lasting clinical response by guaranteeing consolidated results with few AEs.
Contributions are made by leaders and stakeholders from psoriasis, psoriatic arthritis, pediatric hidradenitis suppurativa, acne, vitiligo, actinic keratosis, alopecia areata, itch, and cutaneous lymphoma workgroups in International Dermatology Outcome Measures (IDEOM): Report from the 2021 Annual Meeting.
A split face design allows subjects to test both products simultaneously in Vehicle Formulation Impacts Tolerability and Patient Preference: Comparison of Tretinoin Branded Lotion and Generic Cream.
PubMed and American Academy of Dermatology records from 2009-2019 are searched in Persistence With Biologic Treatments in Psoriasis: A Structured Literature Review of Studies Using Administrative Database and Clinical Registry Data.
In Pediatric Verrucous Psoriasis: A Case Report in a Pediatric Patient and Discussion of the Literature presents in an adolescent male one of the fewer than 40 documented instances of VP.
A 55-year-old female is the first reported case in Rituximab-Induced Alopecia Universalis in a Patient With Bullous Pemphigoid.
Severe Psoriasis Presenting in 3-Year-Old Child With Nail Dystrophy: Response to Biologic Treatment states that as of 2021, 4 biologic agents have been approved for pediatric use.
“I’m Off My Meds”: Public Perception of Interactions Between SARS-CoV-2 Vaccines and Anti-Psoriatic Treatments Online analyzes the content and sentiment of social media posts on publicly accessible Facebook and Redditt groups.
Two patients note complete prevention of mosquito bites on the nights when 1% IVM cream was applied in Novel Use of Topical Ivermectin for the Prevention of Facial Insect Bites
A goal of A Roadmap for the Development of a Diverse and Inclusive Medical Student Dermatologic Curriculum is to have SOC featured in a minimum of 35% of photographs, mirroring the patient population served in metro Atlanta.
Usage of Topical Calcineurin Inhibitors in the Medicare Population from 2013 to 2018 reports prescription totals and costs for branded pimecrolimus, branded tacrolimus, and generic tacrolimus.
Eight patients are followed for at least 20 weeks in Nail Psoriasis Improvement During Tildrakizumab Therapy: A Real-Life Experience
Post-Residency Training Instead of Medical Student Research Fellowships Will Improve Dermatology Patient Care and Excellence advocates for attention to applicants’ academic metrics as well as experiences and volunteerism, with less emphasis on publications, to decrease pressure on medical students to pursue gap-year fellowships and incur associated costs.
Find more JDD Issue Highlights here.
